# Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer

> **NCT01126450** · PHASE1 · TERMINATED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 3 (actual)

## Conditions studied

- Colon Cancer
- Rectal Cancer

## Interventions

- **DRUG:** lenalidomide
- **BIOLOGICAL:** cetuximab
- **OTHER:** mutation analysis
- **OTHER:** polymerase chain reaction
- **GENETIC:** polymorphism analysis

## Key facts

- **NCT ID:** NCT01126450
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-10
- **Primary completion:** 2010-11
- **Final completion:** 2010-12
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** low accrual,loss of funding and results from EU study showing drug ineffective.
- **Last updated:** 2012-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01126450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01126450, "Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01126450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*